News & Updates
Event Calendar
June 17, 2013 - 4:00pm
June 22, 2013 (All day)
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
| Title | K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. |
| Publication Type | Journal Article |
| Year of Publication | 2010 |
| Authors | Smith DB, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai H-L, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI |
| Journal | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Volume | 16 |
| Issue | 1 |
| Pagination | 338-47 |
| Date Published | 2010 Jan 1 |
| Abstract | Chronic myeloid leukemia (CML) can be responsive to T-cell-mediated immunity. K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a GM-CSF producing vaccine derived from a CML cell line that expresses several CML-associated antigens. A pilot study was developed to determine if K562/GM-CSF immunotherapy could improve clinical responses to imatinib mesylate (IM) in patients with chronic myeloid leukemia. |
| DOI | 10.1177/0883073809350221 |
| Alternate Journal | Clin. Cancer Res. |
Your Support is the Key
Help children like Matthew unlock their potential by becoming a Partner in Potential.
